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Abstract
Introduction
Psoriasis is a chronic inflammatory disorder associated with both cardiovascular
disease and mood disorders such as depression and anxiety. Multiple behavioral and
physiological processes link depression, psoriasis and atherosclerosis, but
inflammation is a major player implicated in the pathogenesis of all three. Psoriasis is
associated with vascular inflammation, measured by 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (FDG PET/CT), and an increased risk of
myocardial infarction. Vascular inflammation by FDG PET/CT predicts cardiovascular
risk and outcomes. Studies have also shown that patients with psoriasis are more likely
to suffer from comorbid depression and anxiety. However, whether these
comorbidities may accelerate the development of cardiovascular disease in psoriasis is
not well-characterized.

Hypothesis
Our primary hypothesis is that aortic vascular inflammation and coronary
plaque burden will be increased in patients with psoriasis who have depression when
compared to psoriasis patients who do not. In a follow-up study we hypothesize that
metabolic activity in the anatomic location of the amygdala will correlate with
increased vascular inflammation and decreased vascular function.

Methods
An ongoing psoriasis study cohort was chosen for the patient population.
Patients who reported a history of depression (n=36) on survey were matched by age
and sex to patients who reported no history of psychiatric illness (n=36). FDG PET/CT
scans were used to assess vascular inflammation. From these scans, standardized
uptake values were calculated by analyzing axial slices of the aorta. Target-tobackground ratios were then calculated to standardize for background luminal FDG
uptake. Coronary computed tomography angiography scans were analyzed in order to
determine coronary plaque composition and to quantify plaque burden. Multivariate
linear regression analyses were performed to understand the potential effect of
psychiatric diagnoses on aortic vascular inflammation and coronary plaque burden.
Traditional cardiovascular risk factors were adjusted for (standardized β reported). In
a follow-up study, metabolic activity of the amygdala was quantified via analysis of FDG
uptake in the anatomic location of the amygdala. These uptake values were divided by
FDG uptake in the adjacent ipsilateral temporal lobe for standardization. Target-tobackground ratios were then used to quantify amygdala activity. Vascular function was
studied via aortic distensibility. Using phase contrast MRI scans throughout the
duration of one cardiac cycle, axial slices of the aorta were analyzed to calculate aortic
distensibility.

Results
Aortic vascular inflammation and coronary plaque burden were increased in
psoriasis patients with comorbid depression as compared to those without. After

adjustment for Framingham Risk Score, vascular inflammation (β=0.26, p=0.02), total
plaque burden (β=0.17, p=0.03), and non-calcified plaque burden (β=0.17, p=0.03)
associated with comorbid depression. In a subsequent study, patients with comorbid
depression and/or anxiety had higher left amygdala activity. In unadjusted analyses
vascular inflammation significantly associated with amygdala activity, although this
relationship did not retain significance after adjustment for traditional cardiovascular
risk. Aortic distensibility was significantly and inversely associated with left amygdala
activity both in unadjusted analyses and after adjustment for traditional cardiovascular
risk.

Conclusions
Patients with psoriasis who suffer from comorbid depression have greater
burden of subclinical cardiovascular disease. Furthermore, vascular function is reduced
in these patients and correlates with the degree of activity in the amygdala, a region of
the brain that plays an important role in the modulation of stress. Targeted assessment
of psychological stress and mood disorders in psoriasis patients may be warranted for
further cardiovascular risk reduction in this high-risk population.
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Introduction
The Epidemiology of Coronary Artery Disease
In the modern era, cardiovascular disease has emerged as a leading cause of
morbidity and mortality in the United States and around the world. Despite major
advancements in medicine, technology, and healthcare delivery resulting in decreased
overall burden of disease and greater life expectancy, much of these gains have come
from improvements in treatment and prevention in other major fields such as oncology
and infectious diseases. Better understanding of vascular biology, structural heart
disease and cardiovascular risk factors in the 1900s have also contributed to better
preventive care and management, but such improvements have been modest in
comparison. Throughout the last and current centuries, cardiovascular diseases have,
as an aggregate, caused the greatest mortality and disability in the United States.
It is estimated that one in every three Americans dies from cardiovascular
disease. In 2013 in the United States, NHANES data demonstrated an annual mortality
rate of 222.9 per 100,000 persons.(1) Mortality rates differed significantly by race,
gender, and age. Lowest mortality was seen among Hispanic women, with a rate of
136.4 per 100,000 persons, while mortality rates for non-Hispanic white women and
non-Hispanic black women were 183.8 and 246.6 per 100,000 persons, respectively.
Among men, death rates were 197.4, 270.6 and 356.7 per 100,000 persons for
Hispanics, whites and blacks, respectively. Overall, mortality among men was 269.8 per
100,000 as compared to a rate of 184.8 per 100,000 in women. An estimated 65% of all
cardiovascular deaths within that year occurred in individuals age 75 years and older.
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Cardiovascular disease is an overarching classification that comprises stroke,
coronary heart disease, peripheral vascular disease, congenital heart disease, valvular
heart disease, arrhythmias, and heart failure. Within cardiovascular disease, coronary
heart disease is a major contributor to disease burden, disability and mortality.
According to the data from NHANES 2013, coronary heart disease is present in about
6.2% of the U.S. population age 20 years and older. Roughly 1 out of 7 deaths are
attributable to coronary heart disease and a myocardial infarction event is estimated to
occur once every 42 seconds.

Inflammation and Atherosclerosis
In the early 1900s the prevailing thought among physicians and medical
scientists was that the heart was untouchable. The esteemed surgeon Sir Stephen Paget
once said, “no new method, and no new discovery, can overcome the natural difficulties
that attend a wound of the heart”. Yet, in the summer of 1929, a young German
physician by the name of Werner Forssmann had a bold idea to access the human heart
via a long ureteral catheter. So determined was he to bring this idea to fruition that,
enlisting the help of a surgical nurse, he arranged to serve as his own first subject. With
this first attempt, he achieved a successful procedure and ultimately ushered in a new
wave of capabilities for diagnosing and treating heart disease.
In line with advancements in procedural and imaging techniques, our
understanding of the natural history of atherosclerosis and its causal factors has grown
significantly. Our knowledge of the pathways that mediate atherosclerosis and its
progression towards cardiovascular events has expanded considerably in recent
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decades, increasing our ability to provide better preventive care alongside
interventional management. Where we once thought of atherosclerotic plaque
development as arising from the gradual accumulation of lipids in the vessel wall, we
now understand this process to be driven by a concert of interconnected immunologic
pathways encompassing both innate and adaptive systems, as evidenced by the activity
of monocytes, macrophages, T cells and B cells, and by increases in inflammatory
mediators such as M-CSF and C-reactive protein (see Figure 1).(2)

Figure 1: Monocyte and Macrophage Activity in Atherosclerosis

Monocytes migrate through the endothelium and become macrophages. Once activated,
macrophages release several pro-inflammatory and pro-thrombotic mediators that promote
atherosclerotic plaque formation and progression.
Reprinted from Libby P. Inflammation in Atherosclerosis. Nature. 2002; 420: 868-874.

There is a large, multi-disciplinary body of evidence to support the prominent
role of inflammation in cardiovascular disease. Epidemiologic studies of chronic
inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, and
3

psoriasis have been shown to increase the risk of myocardial infarction, stroke and
cardiovascular death.(3,4) In these chronic conditions, systemic inflammation is known
to promote the up-regulation of both innate and adaptive immune pathways, leading to
pro-inflammatory cytokine expression, endothelial activation, vascular inflammation,
and disordered lipid metabolism. The relationship of these atherogenic processes to
disease severity exhibit dose-dependent responses, further supporting a key causal role
for inflammation in atherosclerosis.(5) In many cases, specific immunologic markers
have been directly implicated in atherogenesis using the human clinical models
provided by chronic inflammatory diseases.(6)
These insights extend to the general population as markers of inflammation,
such as High-sensitivity C-reactive protein and Glycoprotein A, are seen to correlate
with cardiovascular disease in healthy volunteers.(7) After statin therapy,
improvements seen in these inflammatory markers demonstrate a direct relationship
with improvement in cardiovascular disease risk.(8) Although statins were originally
created for the purpose of reducing cholesterol via inhibition of the enzyme, HMG-CoA
reductase, the anti-inflammatory activities of statins have become well-understood,
particularly with regards to their ability to reduce the risk of cardiovascular events
independent of cholesterol reduction.(9) Similarly, aspirin, prescribed primarily for its
anti-thrombotic properties, is also known to exhibit anti-inflammatory effects.
However, apart from statins and aspirin, whose anti-inflammatory roles were
discovered secondarily, there are currently no other anti-inflammatory drugs in use in
the general population for the treatment and prevention of cardiovascular disease. We
continue to rely primarily on statins and other lipid-lowering and anti-thrombotic
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drugs to reduce cardiovascular risk, despite mounting evidence that inflammatory
mediators play a major role in promoting atherosclerosis.
Putting together our advancing understanding of the way inflammation drives
atherosclerosis with the associations between immune modulation and cardiovascular
risk seen in observational studies, it has become clear that targeted anti-inflammatory
therapies hold promise for preventing and slowing the pace of atherosclerotic plaque
formation. Towards this end, there are three major trials currently evaluating the
potential use of immunomodulatory drugs to treat coronary artery disease. Two of
these trials look specifically at low-dose methotrexate (TETHYS and CIRT) and the third
studies canakinumab, a human monoclonal antibody against interleukin-1beta
(CANTOS).(10, 11, 12 ) Results from these studies may provide new treatment options
for secondary prevention of cardiovascular disease in high-risk patients.
Despite these encouraging strides, the march towards viable anti-inflammatory
therapies for heart disease has been slow and steady, particularly in translating novel
strategies from basic science and pre-clinical studies into human clinical trials. For
example, researchers in nanomedicine have developed methods for specifically
localizing delivery of, IL-10, a potent anti-inflammatory mediator, to atherosclerotic
plaques and have been able to demonstrate plaque reduction and stabilization in
preclinical models.(13) If this work can be successfully extended to humans, such
targeted therapies will utilize the body’s own intricate immune signaling pathways to
isolate and treat vascular disease at its source. However, many challenges, including
differences between the way atherosclerosis progresses in humans versus animal
models, complicate the road to discovery in this arena.
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On a different front, novel anti-interleukin therapies are currently being studied in
patients with chronic inflammatory diseases to determine whether opposing
inflammation will lead to improved cardiovascular outcomes.(14) We stand to gain
valuable information from these trials that may be transferrable to the general
population.
The importance of developing targeted therapies for the reduction of
cardiovascular disease has not gone unnoticed. In collaboration with the major
biotechnology companies, Verily Life Sciences and AstraZeneca, the American Heart
Association recently launched an initiative known as “One Brave Idea” to incentivize
and fund research towards finding the cure for coronary heart disease. It is a lofty
endeavor, but one that will be met with an equally impressive financial commitment of
75 million dollars pledged to the selected team.
Given that cardiovascular disease is the world’s leading cause of mortality, the
translation of pharmacologic anti-inflammatory therapies from the laboratory to the
clinic represents a pressing challenge for modern medicine. We now possess the
appropriate basic science foundation to allow for the creation of medical therapies to
better treat and prevent cardiovascular disease by directly attacking its underlying
inflammatory pathways. Clinically available targeted anti-inflammatory therapies for
the primary and secondary prevention of coronary artery disease are hopefully not far
beyond the horizon.
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Psoriasis as a Human Clinical Model of Atherosclerosis
Psoriasis is a chronic inflammatory skin disorder that affects roughly 3.15% of
the U.S. adult population.(15) An estimated 17% of these patients suffer from moderate
to severe disease as defined by 3% or greater body surface area affected. Similar to
atherosclerosis, the pathogenesis of psoriasis involves both the innate and adaptive
immune pathways. The activity of macrophages(16), neutrophils(17) and dendritic
cells(18) are increased in psoriasis patients. Dendritic cells then signal for the
accumulation and differentiation of T cells, which are known to release key cytokines
responsible for mediating skin pathology. In particular, TNF-alpha, IL-17, IL-12 and IL23 play major roles in the development of psoriatic lesions and have been the focus of
targeted therapies. Biologic therapies opposing several of these key mediators have
been approved for the treatment of moderate-to-severe psoriasis. Table 1 provides a
list of FDA approved psoriasis therapies along with their immunologic targets.
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Table 1: Systemic and Biologic Psoriasis Therapies
Drug Class

Drug Names

Mechanism of Action

Systemic Therapies
Antimetabolites

Methotrexate

Inhibits dihydrofolate
reductase activity which
disrupts DNA synthesis,
thereby reducing skin cell
proliferation

Calcineurin inhibitors

Cyclosporine

Down-regulates T cell
activity

Biologic Therapies
TNF inhibitors

Etanercept, Infliximab,

Inhibition of TNF-alpha

Adalimumab
IL-12/23 inhibitors

Ustekinumab

Monoclonal antibody that
antagonizes IL 12 and IL-23

IL-17 inhibitors

Phosphodiesterase-4

Secukinumab, Ixekizumab,

Monoclonal antibody against

Brodalumab

IL-17A

Apremilast

Increases intracellular cAMP;

inhibitor

exact mechanism of
therapeutic effect unknown
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Natural history studies and clinical trials have helped scientists to better
understand how the complex process of inflammation translates to cardiovascular
disease. To this end, psoriasis, in particular, has emerged as a useful human clinical
model for studying the development of cardiometabolic diseases such as
atherosclerosis, hypertension, diabetes mellitus, and dyslipidemia. The prevalences of
these comorbid conditions have been shown to be elevated in psoriasis, often in a dosedependent fashion, with rates seen to increase with increasing severity of psoriasis.(19)
Similarly, risk of myocardial infarction has been shown to exhibit a dose-dependent
increase in psoriasis. In one Danish population-based study, rate ratios for all-cause
mortality, cardiovascular mortality, myocardial infarction and stroke were elevated in
psoriasis. Rate ratios of cardiovascular death were found to be 1.14 and 1.57 in mild
and severe psoriasis, respectively.(20) In addition to psoriasis severity, disease onset
was also found to associate with cardiovascular risk. Increased rate ratios of
cardiovascular events were found to associate with earlier onset of psoriasis,
suggesting that disease exposure promotes progression of atherosclerosis over time
and, thereby, further supporting the causal link between psoriasis and cardiovascular
disease.
Psoriasis provides the ideal system within which to study the progression of
cardiovascular disease for several reasons. Firstly, psoriasis is a chronic condition that
is managed over the course of a lifetime. Patients, therefore, experience significant
exposures that can be studied over longer terms and which can be related to outcomes
that require long periods of time to develop such as myocardial infarction and
mortality. Secondly, psoriasis is a condition with highly varied presentations. Severity
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can range from a single, small psoriatic patch to nearly 100% body surface area (BSA)
affected. Severity is commonly classified as mild psoriasis comprising BSA <3%,
moderate psoriasis comprising BSA of 3-10%, and severe psoriasis comprising BSA
>10%.(21) Another reason psoriasis is such an appropriate condition for studying the
intersection of inflammation and cardiovascular disease is the diversity of treatment
options and management decisions. Some patients, particularly those with mild
psoriasis, may opt to receive no treatment. Others may choose topical therapy or UV
light to keep symptoms at bay. Many, particularly patients who have severe psoriasis,
begin stronger, systemic anti-inflammatory therapies. This diversity of treatment
choices provides the opportunity to study atherosclerosis in psoriasis within various
contexts. The natural progression of plaque development can be evaluated in the
absence of any therapy or in the absence of systemic therapy. The effect of systemic
anti-inflammatory drugs can also be studied in psoriasis patients.

Psychological Stress and Atherosclerosis
Psychological stress, is another condition thought to play a role in promoting
atherosclerosis and, much like psoriasis, this connection is thought to occur, at least in
part, via inflammation. Psychological stress, often studied through the common
diagnoses of depression and anxiety, has a complex relationship with atherosclerosis.
However, despite becoming a major area of interest this relationship still remains
poorly characterized. Some of the early observations highlighting the link between
stress and cardiovascular disease involve the documentation of cardiac events such as
myocardial infarction, which have been seen to rise in number during historical
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calamities leading to widespread distress. For example, directly following the
Northridge Earthquake in Los Angeles in 1994, mortality due to myocardial infarction
increased significantly in individuals who did not experience direct physical trauma or
increased physical activity within the population located closest to the epicenter of the
earthquake.(22) Mortality due to other cardiac causes, such as cardiomyopathy,
valvular heart disease and stroke, did not change significantly after the earthquake.
Similarly, mortality due to non-cardiovascular causes was unchanged following the
earthquake, ultimately leading researchers to conclude that distressing events can
insight acute coronary syndromes.
Chronic states of stress like depression also demonstrate a reliable association
with cardiovascular disease in large population-based studies, so much so, that many
believe depression should be formally considered a cardiovascular risk factor. There
are many different mechanisms by which depression is thought to promote
cardiovascular disease.(23) Depression associates with detrimental behaviors such as
alcoholism, sedentary lifestyle, and suboptimal dieting. Although the influence of
behavioral and environmental factors is logical, it does not fully explain why
cardiovascular disease risk is increased in depression. Among young, healthy adult
populations, a strong association has been demonstrated between a clinical diagnosis of
depression and ischemic heart disease beyond adjustment for traditional
cardiovascular risk in the form of Framingham scores.(24) Other causal mechanisms
posited include inflammation, up-regulation of pro-thrombotic mediators, oxidative
stress, and endothelial dysfunction.

11

Several of the key pathways thought to mediate the relationship between
psychological stress and atherosclerosis have been examined. Up-regulation of the
sympathetic nervous system occurs under stress and leads to the systemic release of
catecholamines such as epinephrine and norepinephrine. These catecholamines
promote cardiovascular effects commonly associated with the stress response, such as
increases in vascular tone, cardiac contractility, heart rate and heart rate variability, as
well as evolutionarily adaptive metabolic responses like lipolysis and insulin
resistance.(25) All of these changes are adaptive in the short-term, when high-risk
situations necessitate heightened metabolic activity or swift physical response, but in
chronic states of stimulation, either by external stressors or psychological dysfunction,
these processes become maladaptive and promote vascular dysfunction and
cardiometabolic disease. The hypothalamic-pituitary-adrenal (HPA) axis also responds
to stress by upregulating cortisol release. The resultant chronically elevated levels of
cortisol ultimately promote thrombosis(26) and endothelial dysfunction.(27) Cortisol,
along with catecholamines released, lead to increases in C-reactive protein and IL-6. In
multiple investigations the inflammatory mediators, TNF-alpha and IL-6 have
demonstrated strong associations with depression.(28) Therefore, psychological stress
is intricately linked to cardiovascular disease by multiple physiological mechanisms.
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Figure 2: Proposed Mechanisms Linking Stress to Cardiovascular Disease

Multiple pathways link the stress response to inflammation and cardiometabolic diseases including
the HPA axis and the sympathetic nervous system.
Reprinted from Brotman et al. The cardiovascular toll of stress. Lancet. 2007.
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Psoriasis and Mood Disorders
In addition to being marked by higher cardiovascular risk, psoriasis is also
known to elevate the risk of depression and anxiety. One population-based study from
the United Kingdom identified higher rates of depression, anxiety and suicidality among
patients with psoriasis.(29) After controlling for age, sex, and other comorbid
conditions such as obesity, hypertension, diabetes, hyperlipidemia, and cancer, the
adjusted hazard ratios comparing psoriasis to non-psoriasis controls were 1.39, 1.31
and 1.44 for depression, anxiety and suicidality, respectively. Similar to what was seen
in studies examining the relationship between psoriasis and cardiovascular risk,
psoriasis was shown to exhibit a dose-dependent relationship with risk of depression.
Additionally, a significant age interaction was identified, showing that younger psoriasis
patients experienced the greatest risk for depression. There is also evidence to suggest
that the psychological repercussions of psoriasis are greater for younger patients.
Early-onset psoriasis, namely psoriasis that present in ages < 20 years, associates with
increased severity of both depression and anxiety when compared to those for whom
psoriasis presents at an older age.(30) Patients with psoriasis, therefore, stand to
benefit greatly from targeted mental health screening and care that is cognizant of the
psychological comorbidities that accompany the condition.
While depression and anxiety often go hand-in-hand with psoriasis, specific
therapies for the treatment of psoriasis can help to improve these comorbidities.
Ustekinumab is a monoclonal antibody that targets interleukins 12 and 23, two
cytokines known to play a central role in the pathophysiology of psoriasis. In one
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randomized control trial, it was shown that administration of ustekinumab, when
compared to placebo, resulted in improvements in standardized scores for symptoms of
anxiety and depression.(31) One might expect that as psoriasis symptoms are
alleviated, symptoms of depression and anxiety should also improve. Interestingly,
however, there are some scientists who purport that the relationship between psoriasis
and mood disorders is bidirectional rather than unidirectional. Although there is little
in the way of direct evidence to demonstrate that depression or psychological stress
drives the onset of psoriasis, patients often recount that psoriasis onset and or flares
can occur in the setting of significant life stress. A singular, but persuasive example of
this is the case of a 28-year old woman with schizoaffective disorder in whom psoriasis
flares closely coincided with acute worsening of her mood and mental state.(32)
Another study observed that patients reporting stressful life events were more likely to
be experiencing active spread of psoriatic lesions.(33)
Due to the increased risk of cardiovascular disease coupled with an increased
burden of psychological stress and mood disorders, patients with psoriasis represent
an especially high-risk population for the progression of atherosclerosis and
development of adverse cardiovascular events. At the intersection of these comorbid
conditions lies a complex entanglement of causal factors, the contributions of which still
need to be better clarified. For now, what we do know is that patients with psoriasis
who suffer from comorbid depression experience the highest rates of myocardial
infarction, stroke and cardiovascular death.(34) How much of this is due to behavioral
factors, genetic predisposition, or physiological processes set in motion by the
inflammatory insults of psoriasis or depression is unknown as our current
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understanding of the ways in which chronic inflammation and depression interact to
accelerate atherosclerosis is not yet well-developed.
Patients with psoriasis represent a particularly high-risk population for the
development of cardiovascular disease due to the “double-whammy” of chronic
inflammation and higher rates of depression and anxiety. Aortic vascular inflammation
as measured by 18-FDG PET/CT has been previously used as a measure of subclinical
vascular disease and has been correlated with future cardiovascular events.(35)
Coronary computed tomography angiography provides a validated, non-invasive tool
for quantifying coronary plaque burden and is similarly correlated with future
cardiovascular events.(36) Amygdala activity, quantified by FDG PET/CT, has also been
validated as a biological measure of psychological stress.(37) These non-invasive
imaging modalities provide a useful way to examine the progression of atherosclerosis
in patients with chronic inflammation and better understand the effects of comorbid
psychological stress on subclinical cardiovascular disease in this high-risk population.
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Statement of purpose
Specific Aims
The goal of this study was to evaluate the degree of subclinical vascular disease
and vascular dysfunction associated with self-reported depression as well as amygdala
activity in a well-phenotyped cohort of psoriasis patients.

Hypothesis
In this population, we hypothesized that patients who reported comorbid
depression would experience greater vascular inflammation and coronary plaque
burden beyond what is attributable to traditional cardiovascular risk. Furthermore, we
hypothesized that the degree of metabolic activity in the region of the amygdala would
associate with increased vascular inflammation and decreased vascular function in
patients with psoriasis.
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Methods
Patient Selection
The patient cohort for this study was derived from a larger psoriasis patient
cohort used to study the relationship between psoriasis and cardiovascular health at
the National Institutes of Health (NCT01778569). Patients were recruited via flyers
and advertisement at local dermatology clinics to the protocol 13-H-0065 beginning on
January 23, 2013 and continuing until October 14, 2015. Prior to the recruitment of
patients, approval for this research was granted by the Institutional Review Board for
the National Heart Lung and Blood Institute. All enrolled patients provided informed
consent before participating in this study.
Patients over the age of 18 years who had a diagnosis of psoriasis made by a
dermatologist or a collaborating board-certified physician were included in this study.
Exclusion criteria included pregnancy, women currently lactating, and kidney disease
with an estimated glomerular filtration rate less than 30mL/min/1.73m2. Upon
enrollment patients were seen at the National Institutes of Health Clinical Research
Center for a baseline visit. During this visit a detailed history and physical exam were
performed. Several questionnaires were also administered to gather key details and
data on potential covariates. In one of these baseline medical questionnaires, study
participants were asked to report a history of depression, anxiety, or other psychiatric
illness as defined by the use of medications and/or counseling services. In total, 36
patients reported a history of depression. These patients were then matched by age
and sex to 36 psoriasis patients who reported no history of psychiatric illness on the
same questionnaire.
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Clinical Assessment
All clinical assessments and scans were completed at the National Institutes of
Health Clinical Research Center. At their baseline visits, all patients received FDG
PET/CT scans. Patients who provided their consent and who did not have any
contraindications to IV contrast also received coronary CT angiograms. Patients who
consented and did not have contraindications to MRI also underwent FDG PET/MRI
scanning. All patients provided blood samples to be analyzed in the laboratory for
immunologic and lipid profiling. Fasting blood samples were drawn during the baseline
visit and immediately sent to an on-site certified research laboratory for processing.
Key measurements included levels of glucose, insulin, triglycerides, LDL, HDL, total
cholesterol, CRP, IL-6, IL-12, IL-17, IL-23, and TNF-alpha.

Vascular FDG/PET CT Analysis
In preparation for FDG PET/CT scans, patients were asked to fast overnight
prior to their visits. During their baseline visits patients received a 10mCi dose of 18fluorodeoxyglucose (FDG) tracer. Roughly 60 minutes later patients were scanned and
PET/CT images were acquired using a Siemens Biograph mCT PET/CT 64-slice scanner
(Siemens Medical Solutions USA, Malvern, PA, USA). PET/CT images were then
processed and analyzed as 1.5mm thick slices in a dedicated software program known
as Extended Brilliance Workspace (Phillips Electronic, NV, USA). On each 1.5mm axial
slice, circular contours, known as regions of interest, were placed around the walls of
the aorta (Figure 3A). When placing regions of interest, adjacent anatomic structures
were carefully avoided in order to prevent inaccurate measurement of FDG uptake.
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Standardized uptake values of FDG uptake were calculated using the semi-automated
Extended Brilliance Workspace program.
Figure 3: Plaque imaging by coronary CT and aortic vascular inflammation by FDG
PET/CT

A

B

A) FDG PET/CT imaging of a patient with psoriasis and comorbid depression shows FDG uptake in the aortic
wall indicative of increased macrophage activity and vascular inflammation. B) CT imaging of the right
coronary artery of a patient with psoriasis as well as comorbid depression and anxiety is shown in 4 slices.
QAngio software delineates the vessel wall (orange line) and lumen (yellow line) and shows areas of
increased wall volume to be quantitated and characterized (arrow).
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Mean and maximum standardized uptake values were then determined for each
axial slice and, eventually, for each segment of the aorta (1=ascending, 2=aortic arch,
3=descending, 4=suprarenal, 5=infrarenal). Regions of interest were also placed
around the lumen of the superior vena cava, excluding the vessel wall, on 10
consecutive axial slices. A new variable, known as the target-to-background ratio, was
calculated by dividing the maximum standardized uptake value of each slice by the
mean standardized uptake value of the superior vena cava. Target-to-background ratio,
therefore, represents the amount of 18-FDG uptake, or in other words, metabolic
activity in the aortic wall only, excluding the contribution of luminal activity.

Coronary CT Angiography Scanning
Patients who provided informed consent and were eligible to receive coronary
CT angiography were scanned using a 320 detector row unit (Aquilion ONE ViSION
Edition; Toshiba Medical Systems, Otawara, Japan) on the same day as their baseline
clinical visits. Coronary CT angiography images were analyzed by an experienced
collaborating cardiologist. Using a dedicated software program, QAngio CT (Medis, The
Netherlands), scans were loaded and analyzed to quantify coronary plaque burden by
composition (Figure 3B). Total, non-calcified, and dense calcified plaque were
identified based on pre-defined Hounsfield unit ranges and quantified in the major
coronary vessels: the left main, left anterior descending, left circumflex and right
coronary arteries. Each coronary artery was analyzed individually for total, noncalcified and dense calcified plaque burden by dividing the plaque volume of each
artery by its length.
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Amygdala Uptake by FDG PET/CT
In a follow-up study, patients from the same psoriasis cohort (NCT01778569)
who reported on baseline survey either a history of depression, anxiety or both, were
selected (N=41). Those selected patients were then matched by age and sex to patients
from the same cohort who reported no history of psychiatric illness (N=41). Metabolic
activity in the amygdala was quantified by FDG PET/CT using a dedicated image
processing program (OsiriX MD, Geneva, Switzerland). Spherical regions of interest
were placed in the specific anatomic location of the amygdala on 1.5mm thick axial cuts
of the FDG PET/CT scans. Mean standardized uptake values were quantified by the
program based on the amount of FDG uptake found within each region of interest
placed. All regions of interest were placed by the same analyst, who was also blinded to
clinical data. In addition to measuring uptake in the anatomic location of the amygdala,
standardized uptake values were also measured in the ipsilateral temporal lobes in the
same axial plane to provide a background for standardization of patient scans. The
mean standardized uptake values of the amygdala were divided by the mean
standardized uptake values of the corresponding temporal lobe in order to calculate
target-to-background ratios. Studies have shown the left amygdala to be better
correlated with psychological stress.(38) Therefore, this study focused on findings
from the left amygdala.
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Figure 4: FDG PET/CT Analysis of Amygdala Activity

Regions of interest are placed in the anatomic location of the amygdalae and adjacent
temporal lobes to quantify FDG uptake.

Aortic Distensibility by Phase Contrast MRI
Aortic distensibility was also used in this study as a measure of vascular
function. Distensibility of the aorta was determined by placing contours on the walls of
the descending aorta on axial slices of the phase contrast MRI scans throughout the
entirety of one cardiac cycle. A different analyst who was also blinded to clinical data
performed all aortic contouring for phase contrast MRI. Distensibility of the aorta was
then calculated using the measurements of the descending aorta on transverse axial
slices throughout the cardiac cycle. The following formula was used to determine
distensibility: [(maximum area – minimum area) x 100]/[(minimum area) x (pulse
pressure)].
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Statistical Analyses
Descriptive statistics were generated using STATA 12.1 statistical software
(StataCorp, College Station, TX, USA). Skewness and kurtosis measures were used to
determine whether or not the distribution of each covariate was normal. For
continuous variables that were normally distributed, the Student’s t-test was used. For
continuous variables that were not normally distributed, the Mann-Whitney U test was
used. Comparisons of dichotomous variables were performed using Fisher’s exact test.
Multiple regression analyses were run to evaluate potential relationships.
To examine the relationship between depression and subclinical atherosclerosis,
self-reported depression was considered the primary independent variable and aortic
target-to-background ratio was considered the primary dependent variable.
Univariable regression analyses were initially performed to evaluate the association
between the primary variables. Total and non-calcified coronary plaque burden were
considered secondary outcomes dependent on the primary independent variable.
Multivariable linear regression analyses were then conducted to determine the
relationship between self-reported depression and target-to-background ratio, as well
as between self-reported depression and total and non-calcified plaque burden, after
adjustment for traditional cardiovascular risk in the form of Framingham risk score. In
a second, follow-up study of the same cohort, logistic regression analyses were used to
evaluate the association between amygdalar target-to-background ratio and aortic
target-to-background ratio. The same stastical models were used to report the
association between amygdalar target-to-background ratio and aortic distensibility.
Beta coefficients and p-values were given to report on the strength of each relationship
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found. All of the statistical analyses performed in this study were conducted using
STATA 12.1 statistical software.

Statement of Work Completed by the Author
As the author of this thesis, I, Tsion Aberra, attest that I conceived of the original
scientific question regarding the relationship between depression and vascular
inflammation in psoriasis. I generated the initial hypothesis and constructed the
patient cohort for this nested cohort study. Using the clinical database from the larger
study, I selected patients based on depression/anxiety status reported on baseline
survey and performed matching by age and sex to form the study arms. I performed all
statistical analyses using pre-generated data from the larger study. Clinical data, aortic
FDG PET/CT, coronary CT angiography and phase contrast MRI were measured and
recorded by other members of the laboratory. I was involved in a collaborative effort to
retrieve and enter clinical and imaging data for ongoing patient visits. Under the
guidance of a collaborating neuroradiologist, I placed all regions of interest on FDG
PET/CT brain scans for a follow-up study on the same cohort of patients. I included 5
patients with anxiety only, who had not previously been included in order to increase
the sample size and expand the overall scope of primary question to include anxiety in
addition to depression. While placing regions of interest on pre-specified anatomic
locations in the brain, I was blinded to clinical data, as patients were de-identified and
given new tracking numbers during this process. I performed all statistical analyses for
this follow-up study.
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Results
Patients in both study groups were similar in age (overall average age= 48.9
years) and gender distribution (50% male in each group). In both groups patients had
low Framingham risk scores on average and mild-to-moderate psoriasis as measured
by Psoriasis Area and Severity Index scores (Table 2). Major clinical parameters and
cardiovascular risk factors, such as hypertension, diabetes, hyperlipidemia and family
history of coronary artery disease did not differ significantly between groups.
In psoriasis patients who reported a history of depression, vascular
inflammation, as assessed by FDG PET/CT target-to-background ratio, was significantly
higher than in psoriasis patients who reported no history of psychiatric illness (Table
3A). After adjustment for Framingham risk scores, these differences remained
significant (Table 4A). In patients using systemic or biologic anti-inflammatory
therapies, the relationship between self-reported depression and aortic vascular targetto-background ratio did not retain significance. However, in patients who did not use
systemic or biologic anti-inflammatory therapies, an even stronger relationship was
observed between depression and aortic target-to-background ratio, than was seen in
the overall cohort (Table 5).
Patients with self-reported depression were found to have significantly higher
total and non-calcified coronary plaque burden, assessed by coronary CT angiography
(Table 3B). After adjustment for Framingham risk scores the relationship between
depression and both total and non-calcified coronary plaque burden remained
statistically significant (Table 4B). In patients using systemic or biologic therapies,
these relationships did not retain significance, while in patients who were not using
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systemic or biologic therapies, even stronger relationships between depression and
both total and non-calcified coronary plaque burden were observed (Table 5). No
significant differences were observed between study groups for dense calcified
coronary plaque burden.
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Table 2: Patient Characteristics
Parameters

Psoriasis with

Psoriasis without

P

depression, N=36

depression, N=36

Age (years)

48.7 ± 12.4

49.0 ± 12.3

matched

Males, N (%)

18 (50%)

18 (50%)

matched

Body Mass Index

30.0 ± 6.6

28.5 ± 4.7

0.13

Hypertension, N (%)

13 (36%)

7 (19%)

0.11

Type 2 diabetes, N (%)

3 (8%)

3 (8%)

1.00

Hyperlipidemia, N (%)

17 (47%)

17 (47%)

1.00

Current tobacco use, N (%)

7 (19%)

7 (19%)

0.17

Personal history of CAD, N (%)

2 (6%)

3 (8%)

0.64

Family history of CAD, N (%)

11 (31%)

15 (42%)

0.33

Exercise frequency ≥ once weekly, N (%)*

29 (88%)

29 (94%)

0.44

Systolic BP, mmHg

125.5 ± 19.0

120.2 ± 14.7

0.10

Diastolic BP, mmHg

74.1 ± 10.2

71.3 ± 10.3

0.13

Total cholesterol, mmol/L

4.79 ± 1.03

4.57 ± 0.99

0.18

LDL cholesterol, mmol/L

2.75 ± 0.84

2.56 ± 0.79

0.17

HDL cholesterol, mmol/L

1.35 ± 0.42

1.44 ± 0.43

0.17

Framingham Risk score [median (IQR)]

4 (1-6)

2.5 (1-5)

0.56

Hs-CRP, nmol/L [median (IQR)]

20.95 (9.71-41.43)

22.86 (6.67-62.86)

0.84

Disease duration, years

22.3 ± 15.5

20.5 ± 15.3

0.31

Body surface area affected, % [median (IQR)]

4.5 (2.8-17.4)

3.4 (1.7-13.2)

0.34

PASI score [median (IQR)]

6.3 (3.2-13.7)

4.7 (2.8-12.8)

0.25

Systemic or biologic therapy, N (%)

12 (33%)

14 (39%)

0.62

Demographics and clinical history

Cardiovascular risk profile

Psoriasis characteristics

Continuous variables are expressed as Mean ± Standard Deviation unless specified otherwise.
Hs-CRP . High sensitivity C-reactive protein, PASI . Psoriasis Area and Severity Index. *N = 33 vs. 31.
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Table 3: Markers of Subclinical Atherosclerosis. (A) Vascular Inflammation by
Depression Status. (B) Coronary Plaque Burden by Depression Status
Parameter

Comorbid depression No psychiatric history

P

A
Vascular inflammation by FDG-PET/CT
Total aortic TBR

1.82 ± 0.34

1.66 ± 0.18

0.008

Aortic arch TBR

1.98 ± 0.36

1.84 ± 0.21

0.02

Descending aortic TBR

1.81 ± 0.37

1.65 ± 0.18

0.01

Suprarenal aortic TBR

1.90 ± 0.42

1.69 ± 0.24

0.007

Infrarenal aortic TBR

1.79 ± 0.40

1.59 ± 0.19

0.003

1.11 (0.85-1.49)

0.98 (0.81-1.22)

0.04

1.10 (0.83-1.45)

0.93 (0.78-1.21)

0.03

0.01 (0.005-0.03)

0.01 (0.003-0.03)

0.37

B
Plaque burden adjusted for luminal attenuation
Total burden (x 100), mm2
[median (IQR)]
Non-calcified burden (x
100), mm2 [median (IQR)]
Dense calcified burden (x
100), mm2 [median (IQR)]
TBR= Target-to-Background Ratio.
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Table 4: Multivariate Analyses of (A) Vascular Inflammation and (B) Coronary
Plaque Burden by Depression Status.
Model

β (95% Confidence Interval)

P

Unadjusted

0.28 (0.032- 0.290)

0.02

Adjusted for FRS

0.26 (.022- 0.280)

0.02

Unadjusted

0.25 (0.010- 0.287)

0.04

Adjusted for FRS

0.23 (0.002- 0.282)

0.047

Unadjusted

0.27 (0.022- 0.288)

0.02

Adjusted for FRS

0.25 (0.009- 0.275)

0.03

Unadjusted

0.29 (0.045- 0.367)

0.01

Adjusted for FRS

0.27 (0.035- 0.360)

0.02

Unadjusted

0.32 (0.058- 0.351)

0.007

Adjusted for FRS

0.30 (0.054- 0.350)

0.01

Unadjusted

0.18 (0.0005- 0.005)

0.02

Adjusted for FRS

0.17 (0.0002- 0.005)

0.03

Unadjusted

0.18 (0.0005- 0.005)

0.02

Adjusted for FRS

0.17 (0.0003- 0.005)

0.03

A
Total aorta

Aortic arch

Descending aorta

Suprarenal aorta

Infrarenal aorta

B
Total plaque burden

Non-calcified burden
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Table 5: Stratified analysis of use of systemic/biologic therapies. (A) Vascular
inflammation, coronary plaque burden and depression status relationship
stratified by systemic/biologic therapy use. (B) Multivariate analyses stratified
by systemic/biologic therapy use.

A
Parameter

No systemic/biologic (N=46)
Dep

No Dep

(N=24)

(N=22)

Aortic TBR

1.85 ± 0.37

1.61 ± 0.14

Total plaque

1.46 ± 1.12

1.42 ± 1.10

p-value

Systemic/biologic (N=26)
Dep

No Dep

P

(N=12)

(N=14)

0.003

1.75 ± 0.28

1.73 ± 0.21

0.42

1.05 ± 0.35

0.006

1.11 ± 0.32

1.11 ± 0.46

0.49

1.02 ± 0.36

0.006

1.09 ± 0.31

1.09 ± 0.46

0.49

burden
Non-calcified
burden
Dep= Self-reported Depression.
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B
Model

No systemic/biologic

β (95% CI)

P

Systemic/biologic

β (95% CI)

P

Relationship between total aortic vascular inflammation and self-reported depression
Unadjusted

0.39 0.071- 0.421)

0.007

0.04 (-0.179- 0.219)

0.84

Adjusted for FRS

0.40 (0.073- 0.422)

0.007

-0.09 (-0.223- 0.144)

0.64

Adjusted for FRS and PASI score

0.30 (0.024- 0.344)

0.03

-0.11 (-0.251- 0.573)

0.57

Relationship between total plaque burden and self-reported depression
Unadjusted

0.24 (0.0009- 0.007)

0.01

0.002 (-0.002- 0.002)

0.98

Adjusted for FRS

0.23 (0.0008- 0.007)

0.02

-0.03 (-0.002- 0.002)

0.79

Adjusted for FRS and PASI score

0.23 (0.0007- 0.007)

0.02

-0.07 (-0.003- 0.002)

0.62

Relationship between non-calcified plaque burden and self-reported depression
Unadjusted

0.24 (0.0009- 0.007)

0.01

0.002 (-0.002- 0.002)

0.98

Adjusted for FRS

0.23 (0.0008- 0.007)

0.01

-0.04 (-0.002- 0.002)

0.78

Adjusted for FRS and PASI score

0.23 (0.0007- 0.007)

0.02

-0.07 (-0.003- 0.002)

0.61

FRS= Framingham Risk Score, PASI= Psoriasis Area and Severity Index.

In a follow-up study evaluating the relationship between amygdala activity and
vascular inflammation as well as vascular function, subjects in both groups had similar
clinical characteristics. Patients with a history of depression and/or anxiety had
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significantly higher mean left amygdala activity than those reporting no psychiatric
history (Table 6). On unadjusted linear regression analysis amygdala activity was
associated with aortic target-to-background ratio on FDG PET/CT (β=0.26, p=0.02).
Amygdala activity also exhibited a strong, inverse relationship with aortic distensibility
on unadjusted regression analysis (β=-0.50, p<0.001). Furthermore, the observed
relationship between amygdala activity and aortic distensibility persisted after
adjustment for Framingham Risk score and systolic blood pressure (β=-0.32, p=0.01).
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Table 6: Follow-Up Study on Amygdala Activity Patient Characteristics
Self-Reported Psych
Diagnosis
N=41

Parameter

No Self-Reported Psych
Diagnosis
N=41

P

Demographics and Clinical Characteristics
Age, years

49.1±13.0

49.3±12.9

0.47

Males, n (%)

20 (49)

20 (49)

1

Body mass index, kg/m2

30.0±6.4

28.3±4.6

0.08

Hypertension, n (%)

14 (34)

9 (22)

0.22

Type-2 diabetes, n (%)

4 (10)

3 (7)

0.69

Hyperlipidemia, n (%)

20 (49)

19 (46)

0.83

Current tobacco use, n (%)

7 (17)

3 (7)

0.18

125.8±18.2

120.4±14.8

0.07

73.6±10.1

72.0±10.5

0.24

Total Cholesterol, mg/dL

185.0±38.5

179.4±38.2

0.25

LDL cholesterol, mg/dL

106.1±32.0

97.1±32.7

0.11

HDL cholesterol, mg/dL

50.6±16.0

58.8±19.4

0.02

Triglycerides, mg/dL

115 (90-179)

92 (76-119)

0.02

Framingham risk score

4 (1-6.5)

2 (1-4)

0.31

HOMA-IR

3.4 (1.6-5.6)

2.6 (1.7-3.6)

0.28

Apolipoprotein A, mg/dL

152.7±27.9

159.9±34.3

0.15

Apolipoprotein B, mg/dL

92.9±19.0

87.0±20.1

0.09

22.2±14.7

20.3±15.6

0.29

5.4 (3.1-12.3)

5.1 (2.8-12.8)

0.46

Clinical and Lab Parameters
Systolic blood pressure, mm
Hg
Diastolic blood pressure, mm
Hg

Psoriasis Characteristics
Disease duration, years
PASI score

Amygdala Target-to-Background Ratio
Left Amygdala TBR

0.85±0.09

0.81±0.09

0.01

Values are reported as mean±S.D. or median (IQR) for continuous variables and as N (%) for categorical
variables. P values are calculated by student’s t-test or Mann-Whitney U-test for continuous variables
depending on the normality and by Pearson’s chi-square test for categorical variables. HOMAIR=Homeostatic Model Assessment of Insulin Resistance, PASI=Psoriasis Area Severity Index,
TBR=Target-to-Background Ratio.
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Discussion
Context and Significance
This study is the first to evaluate the association between self-reported
depression and vascular inflammation in patients with the chronic inflammatory
disorder, psoriasis. We show that psoriasis patients who report comorbid depression
experience significantly increased vascular inflammation, total coronary plaque burden,
and non-calcified coronary plaque burden. We also show that these observed increases
exist after adjustment for Framingham risk, suggesting that depression itself may play a
role in promoting subclinical atherosclerosis beyond what is attributable to traditional
cardiovascular risk.
A stratified analysis of the patient cohort revealed that the relationship seen
between self-reported depression and markers of subclinical atherosclerosis is stronger
in the absence of systemic or biologic treatment and diminished by the use of these
anti-inflammatory therapies. These findings suggest that anti-inflammatory therapy
may modify the relationship between depression and cardiovascular disease in
psoriasis. Overall, the results of this study support the notion that patients with
psoriasis, who are already at increased cardiovascular risk due to chronic inflammation,
incur even greater risk with comorbid depression that is not attributable to traditional
cardiovascular risk factors. Careful screening for psychiatric comorbidities and
provision of appropriate mental health care for patients with psoriasis may be
warranted for further prevention of atherosclerosis.
Over the years, several studies have pointed at depression as a causal factor in
cardiovascular disease.(39,40) Depression has been shown to correlate with
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myocardial infarction, stroke and sudden death.(41,42) Both depression and anxiety
have been associated with atherosclerosis, although to differing degrees. Therefore, we
chose to include patients who reported suffering from both depression and anxiety
concurrently, in addition to patients reporting depression alone. Nonetheless, it is
important to keep in mind that causal mechanisms are complex and may differ between
the two mood disorders in terms of their impact on atherosclerosis.
As cardiovascular imaging techniques have improved, availability of accurate,
non-invasive modalities have led to a greater focus on early markers of cardiovascular
disease. These modalities allow us to better understand the process of atherosclerosis
as it occurs, before the onset of devastating cardiovascular events. The existing
literature examining psychological stress as an independent driver of atherosclerosis is
small, but growing. The data we do have seem to support the idea that psychological
stress promotes atherosclerosis and that this process is at least in part mediated by
inflammation. The results from this study lend further support to the existing evidence
by showing that subclinical cardiovascular disease is increased in psoriasis patients
with self-reported depression beyond what is attributable to traditional cardiovascular
risk.
In a subsequent study of a similar patient population we follow-up our previous
results by quantifying psychological stress using amygdala uptake of FDG on FDG
PET/CT scans of the brain. A recent study of 293 healthy patients conducted at
Massachusetts General Hospital demonstrated a robust relationship between amygdala
activity and cardiovascular events, bone marrow activity and arterial inflammation.(43)
Our follow-up study reinforces and expands upon the findings from this recent study
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conducted in a low-risk population of patients without coronary artery disease. We are
able to show in a psoriasis population that both that left amygdala FDG uptake targetto-background ratio is increased in patients who report a history of depression and/or
anxiety, and that these patients experience greater vascular inflammation and
decreased vascular function. Furthermore, we go on to show that vascular function
remains significantly associated with left amygdala uptake after adjustment for
Framingham risk, suggesting that the extent of vascular dysfunction cannot be fully
attributed to traditional cardiovascular risk. These findings further underscore the
impact of psychological stress on cardiovascular disease. In this study we are able to
observe the atherosclerotic process at an earlier stage in the natural history, but where
vulnerable patients already begin to diverge from their counterparts with less
psychological burden.

Strengths and Limitations
The strengths of this study are that it uses a deeply-phenotyped cohort of
patients, validated non-invasive cardiovascular imaging modalities are used to examine
intermediate outcomes, and that psychological stress is examined in two different ways:
self-reported diagnosis and imaging of the amygdala, a region of the brain involved in
processing stress. Limitations include the sample size, lack of longitudinal data for
follow-up and the lack of standardized metrics for quantifying psychological stress such
as depression inventories. In the future, larger studies that follow patients out several
years to observe the progression of disease burden will allow for a better
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understanding of the impact of psychological stress on atherosclerosis in patients with
and without chronic inflammation.

Conclusion
Overall, in this study we demonstrate that psychological stress in patients with
the chronic inflammatory disorder, psoriasis, associates with greater subclinical
cardiovascular disease and vascular dysfunction. Chronic stress may, therefore, play a
key role in the development and progression of atherosclerosis beyond what can be
explained by links to detrimental lifestyle or traditional cardiovascular risk. As this is a
small, cross-sectional study, causation cannot be determined from the results of this
work, however, we provide the basis from which future studies may further evaluate
the mechanistic links between chronic inflammation, psychological stress and
cardiovascular disease. Furthermore, we identify a patient population that is at even
greater risk of cardiovascular disease through comorbid psychiatric disease, which may
not be well-served by conventional prognostication methods that do not take such
comorbidities into account. Patients who suffer from psoriasis and other chronic
inflammatory diseases may benefit from better risk stratification that is inclusive of
psychological stress and targeted care for psychiatric comorbidities in order to reduce
future risk of adverse cardiovascular outcomes.
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